On November 6, 2023, CMS held a Medicare Drug Price Negotiation Patient-Focused Listening Session for the selected drug Imbruvica. Ten participants were selected to speak, including patients, patient advocates, and researchers. Participants were limited to three minutes, during which time they were asked to address:
Imbruvica is a kinase inhibitor manufactured by Pharmacyclics LLC, an AbbVie company, and Janssen Biotech, Inc. It is indicated for the treatment of adult patients with:
Imbruvica was selected for Medicare drug price negotiation for the Initial Price Applicability Year 2026 based on their total Part D gross covered prescription drug costs from June 2022 – May 2023 of $2.7 billion; a total of 20,000 Medicare Part D enrollees used Imbruvica during this time.
Key Takeaways from Imbruvica Patient-Focused Listening Session
Additional Participant Points
 Note: Participants were asked to not share their last names for confidentiality purposes; some patient advocates identified full names, titles, and organizations.
ADVI will continue monitoring developments and the next steps. This is a delayed release. ADVI Instant content is distributed in real-time for retainer clients. Get in touch to learn more about how we can support your commercialization, market access, and policy needs.